Ipratropium Viatris (Ipratropium Bromide)

Ipratropium Viatris acts on the muscarinic receptors of the respiratory tract to provide bronchodilation and mucus control.

• Chronic obstructive pulmonary disease (COPD): improves airflow, reduces exacerbations, and eases breathing difficulty.
• Asthma: provides bronchodilation, helps control symptoms, and reduces airway secretions.
• Bronchospasm: delivers rapid relief of airway constriction during acute episodes.

• Ipratropium bromide blocks muscarinic (M3) receptors on airway smooth muscle and submucosal glands. By inhibiting acetylcholine-mediated contraction, it induces bronchodilation and decreases mucus secretion, leading to improved airway patency and reduced respiratory resistance.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dry mouth: reduced salivation leading to throat discomfort.
• Cough: irritation of the airway during inhalation.
• Throat irritation: mild soreness or burning sensation.
• Headache: transient mild headache.
• Dizziness: occasional light‑headed feeling.
• Nausea: occasional upset stomach.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing.
• Allergic reaction: rash, itching, swelling, or angioedema.
• Severe tachycardia: rapid heart rate requiring medical attention.
• Urinary retention: difficulty emptying the bladder.
• Exacerbation of narrow‑angle glaucoma: increased intra‑ocular pressure.

Before prescribing Ipratropium Viatris, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Assess renal function: dose may need adjustment in severe renal impairment.
• Monitor anticholinergic effects: watch for dry mouth, urinary retention, or constipation.
• Use caution in narrow‑angle glaucoma: may worsen intra‑ocular pressure.
• Avoid in patients with known hypersensitivity to ipratropium bromide.
• Pregnancy: safety not established; prescriber should weigh benefits and risks.
• Store at room temperature: keep in original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, altering its safety profile or efficacy.

Major Interactions (Avoid)

• Concurrent anticholinergic inhalers: may increase anticholinergic load and side‑effects.
• Beta‑agonists: additive bronchodilation can lead to tachycardia or arrhythmia.
• MAO inhibitors: potential for heightened cholinergic side‑effects.

Moderate Interactions (Monitor Closely)

• Antihistamines: may enhance anticholinergic effects such as dry mouth.
• Tricyclic antidepressants: increased anticholinergic burden.
• Theophylline: monitor for additive respiratory effects and possible toxicity.